Effect of Cetuximab and <i>EGFR</i> Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type <i>EGFR</i> and Use of <i>KRAS</i> as a Possible Biomarker for Treatment ResponsivenessNaomi Miyake, Akira Yamasaki|Yonago acta medica|2019Cited by 5